Original Coverage & Source Attribution: simplywall.st
Intellia Therapeutics (NTLA) has drawn fresh attention after a recent share price pullback. With the stock down over the past month and past 3 months, investors are reassessing expectations around its CRISPR based drug pipeline.
Over the past year, Intellia Therapeutics has combined a sharp year-to-date share price gain of 27.14% with a steep 1-year total shareholder return decline of 52.15%. The recent 30-day share price drop of 8.08% suggests momentum has been fading as investors reassess risk around its pipeline and funding needs.
Scan beyond Intellia Therapeutics and evaluate pressure tested gene editing stories by reviewing the hand picked 34 healthcare AI stocks that screen for similar high risk, high reward healthcare exposure.
After that sharp swing in Intellia Therapeutics, the question now is simple: Does the current valuation still offer enough upside potential to justify the clinical and funding risks investors are taking on?
Most Popular Narrative: 51% Undervalued
Analysts following Intellia Therapeutics see a big gap between the current $11.71 share price and their $23.94 fair value estimate. This puts the focus squarely on whether its CRISPR programs can justify that valuation under a 7.48% discount rate.
Improving financial discipline, as evidenced by successful restructuring, declining GAAP operating expenses (~10% reduction YoY), and a robust cash runway into the first half of 2027, enables Intellia to absorb increased R&D investment, advance pipeline expansion, and build out commercial infrastructure without dilutive fundraising, supporting protection of net margins and improving future earnings visibility.
See why 86 investors see Intellia Therapeutics as 51% undervalued.
Result: Fair Value of $23.94 (UNDERVALUED)
Still, the bullish story around Intellia Therapeutics can unravel quickly if late stage trials stumble or cash burn forces heavier dilution than analysts currently expect.
Find out about the key risks to this Intellia Therapeutics narrative.
Another View On Intellia Therapeutics Valuation
The analyst narrative focuses on future earnings and P/E assumptions, but today Intellia Therapeutics trades on a P/S ratio of 27.6x. That is richer than both the US Biotechs industry at 12.3x and peers at 24.5x, and far above a fair ratio of 0.1x. For investors, that kind of gap suggests meaningful valuation risk if expectations reset.
See what the numbers say about this price and how it compares with similar biotech stocks in our valuation breakdown, starting with the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Mixed on Intellia Therapeutics after all of that, or feeling strongly one way or the other already? Pull up the numbers, weigh the trade off between potential setbacks and upside, and ground your own thesis with the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Intellia Therapeutics?
Do not stop your research with Intellia Therapeutics. Broaden your watchlist with other focused ideas that match different risk levels and income goals using the Simply Wall Street Screener.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Explore Now for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
